<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01655212</url>
  </required_header>
  <id_info>
    <org_study_id>CMV-MM-1</org_study_id>
    <secondary_id>2011-005378-44</secondary_id>
    <nct_id>NCT01655212</nct_id>
  </id_info>
  <brief_title>Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial</brief_title>
  <acronym>CONCERT</acronym>
  <official_title>Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Ann C.T.M. Vossen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting Nuts Ohra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to investigate whether early treatment with oral valganciclovir
      of infants with both congenital cytomegalovirus infection and sensorineural hearing loss can
      prevent progression of hearing loss.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Netherlands all neonates are routinely screened for hearing during the first weeks
      after birth with the Otoacoustic Emissions (OAE) procedure. After the second refer an
      Automated Auditory Brainstem Response (AABR) is performed. The parents of all newborns, born
      at ≥ 37 weeks gestational age, that fail this AABR in the Netherlands (about 550 yearly) will
      be asked for consent for CMV-testing on the dried blood spots. Newborns diagnosed with
      congenital CMV and with confirmed SNHL (≥ 20 dB) are eligible for inclusion. After informed
      consent infants will be randomized before the age of 13 weeks to a treatment group (6 weeks
      valganciclovir 32 mg/kg daily dose; oral solution) or control group (no antiviral treatment).
      Infants will be monitored for leucopenia and liver- and kidney function. Inclusion will
      continue for at least 1.5 years, or until 25 infants in each treatment arm have been
      randomized.

      At 1 year follow-up hearing and child development are assessed. Hearing will be assessed with
      Brainstem Evoked Response Audiometry at an audiological center. Child development will be
      assessed during a home visit with the Bayley Scales of Infant Development III and parents
      will fill in the Dutch Child Development Inventory (NCDI) which will give more detailed
      information on communicative development of their child. Viral loads in blood and urine will
      be monitored during antiviral treatment as well as twice in the control group.

      This study will provide information on the percentage of infants with a congenital CMV
      infection who fail the neonatal hearing screening . The RCT will show whether early treatment
      of congenital CMV infected children with hearing impairment prevents deterioration of hearing
      loss and to what extent. The outcome may lead to implementation of congenital CMV testing in
      the neonatal hearing screening program or possibly into the newborn blood screening.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    1 Indication for further investigations (brain ultrasound). 2 Change of study design to
    efficacy study with historical control group.
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hearing assessment</measure>
    <time_frame>1 year follow-up</time_frame>
    <description>At 1 year follow-up hearing will be assessed with Brainstem Evoked Response Audiometry at an audiological center.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Child development</measure>
    <time_frame>1 year follow-up</time_frame>
    <description>At 1 year follow-up child development will be assessed during a home visit with the Bayley Scales of Infant Development III. Additionally, parents will fill in the Dutch Child Development Inventory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>Baseline, weekly during 7 weeks, and at 1 year</time_frame>
    <description>Viral blood load will be monitored in the treatment group(at baseline, weekly during antiviral treatment, and one week after treatment) as well as in the control group (baseline and 7 weeks after inclusion).
Viral urine load will be monitored in the treatment group and in the control group (at baseline, weekly during 7 weeks after inclusion, and at the age of 1 year).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Congenital Cytomegalovirus Infection</condition>
  <condition>Sensorineural Hearing Loss</condition>
  <arm_group>
    <arm_group_label>Valganciclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remains unchanged.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.</description>
    <arm_group_label>Valganciclovir</arm_group_label>
    <other_name>Valcyte</other_name>
    <other_name>Valganciclovirhydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants with congenital CMV infection and hearing loss (≥ 20 dB, in one or both ears).

          -  Age at time of inclusion is &lt; 13 weeks after birth.

          -  ≥ 37 weeks gestational age.

          -  Birth weight ≥ 2500 gram.

          -  Parental signed informed consent.

        Exclusion Criteria:

          -  Indications for symptomatic congenital CMV infection based on diagnostics carried out
             prior to the inclusion of the child in the trial.

          -  In case during the house visit the presence of a symptomatic CMV infection is doubted,
             inclusion will be discussed. Depending on the medical history taking, physical
             examination and laboratory tests inclusion will be decided upon.

          -  Treatment with other antiviral agents or immunoglobulins.

          -  Leucopenia &lt; 0,5 x 10*9/L (blood sample tested at t=0).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann CT Vossen, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Marie Oudesluys-Murphy, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department Medical Microbiology, Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>Zuid Holland</state>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.lumc.nl/concert</url>
    <description>CONCERT study website</description>
  </link>
  <reference>
    <citation>Kimberlin DW, Lin CY, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Pass RF, Kiell JM, Soong SJ, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003 Jul;143(1):16-25.</citation>
    <PMID>12915819</PMID>
  </reference>
  <reference>
    <citation>Amir J, Wolf DG, Levy I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr. 2010 Sep;169(9):1061-7. doi: 10.1007/s00431-010-1176-9. Epub 2010 Mar 16.</citation>
    <PMID>20232081</PMID>
  </reference>
  <reference>
    <citation>Lackner A, Acham A, Alborno T, Moser M, Engele H, Raggam RB, Halwachs-Baumann G, Kapitan M, Walch C. Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10 year follow up. J Laryngol Otol. 2009 Apr;123(4):391-6. doi: 10.1017/S0022215108003162. Epub 2008 Jun 30.</citation>
    <PMID>18588736</PMID>
  </reference>
  <reference>
    <citation>Oliver SE, Cloud GA, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Pass RF, Soong SJ, Whitley RJ, Kimberlin DW; National Institute of Allergy, Infectious Diseases Collaborative Antiviral Study Group. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol. 2009 Dec;46 Suppl 4:S22-6. doi: 10.1016/j.jcv.2009.08.012. Epub 2009 Sep 18.</citation>
    <PMID>19766534</PMID>
  </reference>
  <reference>
    <citation>Michaels MG, Greenberg DP, Sabo DL, Wald ER. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr Infect Dis J. 2003 Jun;22(6):504-9.</citation>
    <PMID>12799506</PMID>
  </reference>
  <reference>
    <citation>Nigro G, Scholz H, Bartmann U. Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: a two-regimen experience. J Pediatr. 1994 Feb;124(2):318-22.</citation>
    <PMID>8301446</PMID>
  </reference>
  <reference>
    <citation>Whitley RJ, Cloud G, Gruber W, Storch GA, Demmler GJ, Jacobs RF, Dankner W, Spector SA, Starr S, Pass RF, Stagno S, Britt WJ, Alford C Jr, Soong S, Zhou XJ, Sherrill L, FitzGerald JM, Sommadossi JP. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1997 May;175(5):1080-6.</citation>
    <PMID>9129069</PMID>
  </reference>
  <reference>
    <citation>Smets K, De Coen K, Dhooge I, Standaert L, Laroche S, Mahieu L, Logghe N, Cossey V, Boudewyns A. Selecting neonates with congenital cytomegalovirus infection for ganciclovir therapy. Eur J Pediatr. 2006 Dec;165(12):885-90. Epub 2006 Jun 20. Review.</citation>
    <PMID>16786362</PMID>
  </reference>
  <reference>
    <citation>Foulon I, Naessens A, Foulon W, Casteels A, Gordts F. A 10-year prospective study of sensorineural hearing loss in children with congenital cytomegalovirus infection. J Pediatr. 2008 Jul;153(1):84-8. doi: 10.1016/j.jpeds.2007.12.049. Epub 2008 Mar 6.</citation>
    <PMID>18571542</PMID>
  </reference>
  <reference>
    <citation>de Vries JJ, Korver AM, Verkerk PH, Rusman L, Claas EC, Loeber JG, Kroes AC, Vossen AC. Congenital cytomegalovirus infection in the Netherlands: birth prevalence and risk factors. J Med Virol. 2011 Oct;83(10):1777-82. doi: 10.1002/jmv.22181.</citation>
    <PMID>21837795</PMID>
  </reference>
  <reference>
    <citation>Korver AM, de Vries JJ, Konings S, de Jong JW, Dekker FW, Vossen AC, Frijns JH, Oudesluys-Murphy AM; DECIBEL collaborative study group. DECIBEL study: Congenital cytomegalovirus infection in young children with permanent bilateral hearing impairment in the Netherlands. J Clin Virol. 2009 Dec;46 Suppl 4:S27-31. doi: 10.1016/j.jcv.2009.09.007.</citation>
    <PMID>19836301</PMID>
  </reference>
  <reference>
    <citation>Fowler KB, McCollister FP, Dahle AJ, Boppana S, Britt WJ, Pass RF. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr. 1997 Apr;130(4):624-30.</citation>
    <PMID>9108862</PMID>
  </reference>
  <reference>
    <citation>Lanari M, Lazzarotto T, Venturi V, Papa I, Gabrielli L, Guerra B, Landini MP, Faldella G. Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected newborns. Pediatrics. 2006 Jan;117(1):e76-83. Epub 2005 Dec 1. Erratum in: Pediatrics. 2006 Apr;117(4):1467.</citation>
    <PMID>16326692</PMID>
  </reference>
  <reference>
    <citation>Lombardi G, Garofoli F, Stronati M. Congenital cytomegalovirus infection: treatment, sequelae and follow-up. J Matern Fetal Neonatal Med. 2010 Oct;23 Suppl 3:45-8. doi: 10.3109/14767058.2010.506753. Review.</citation>
    <PMID>20807160</PMID>
  </reference>
  <reference>
    <citation>Misono S, Sie KC, Weiss NS, Huang ML, Boeckh M, Norton SJ, Yueh B. Congenital cytomegalovirus infection in pediatric hearing loss. Arch Otolaryngol Head Neck Surg. 2011 Jan;137(1):47-53. doi: 10.1001/archoto.2010.235.</citation>
    <PMID>21242546</PMID>
  </reference>
  <reference>
    <citation>Kimberlin DW, Acosta EP, Sánchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud GA, Lakeman FD, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008 Mar 15;197(6):836-45. doi: 10.1086/528376.</citation>
    <PMID>18279073</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2012</study_first_submitted>
  <study_first_submitted_qc>July 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2012</study_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Ann C.T.M. Vossen</investigator_full_name>
    <investigator_title>MD, PhD, Dept of Medical Microbiology</investigator_title>
  </responsible_party>
  <keyword>Cytomegalovirus</keyword>
  <keyword>Congenital infection</keyword>
  <keyword>Sensorineural hearing loss</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Valganciclovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

